E
Evan A. Stein
Researcher at Medpace
Publications - 344
Citations - 38427
Evan A. Stein is an academic researcher from Medpace. The author has contributed to research in topics: Cholesterol & Familial hypercholesterolemia. The author has an hindex of 80, co-authored 340 publications receiving 36392 citations. Previous affiliations of Evan A. Stein include Cornell University & Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI
Estrogen plus progestin and the risk of coronary heart disease
JoAnn E. Manson,Judith Hsia,Karen C. Johnson,Jacques E. Rossouw,Annlouise R. Assaf,Norman L. Lasser,Maurizio Trevisan,Henry R. Black,Susan R. Heckbert,Robert Detrano,Ora L. Strickland,Nathan D. Wong,John R. Crouse,Evan A. Stein,Mary Cushman +14 more
TL;DR: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.
Journal ArticleDOI
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)
Peter B. Jones,Michael H. Davidson,Evan A. Stein,Harold E. Bays,James M. McKenney,Elinor Miller,Valerie A. Cain,James W. Blasetto +7 more
TL;DR: In this paper, a 6-week, parallel-group, open-label, randomized, multicenter trial was conducted to compare rosuvastatin with comparators for other lipid modifications and achievement of National Cholesterol Education Program Adult Treatment Panel III and Joint European Task Force LDL cholesterol goals.
Journal ArticleDOI
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
John J.P. Kastelein,Fatima Akdim,Erik S.G. Stroes,Aeilko H. Zwinderman,Michiel L. Bots,Anton F. H. Stalenhoef,Frank L.J. Visseren,Eric J.G. Sijbrands,Mieke D. Trip,Evan A. Stein,Daniel Gaudet,Raphaël Duivenvoorden,Enrico P. Veltri,A. David Marais,Eric de Groot +14 more
TL;DR: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simVastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein.
Journal ArticleDOI
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
Sylvia Wassertheil-Smoller,Susan L. Hendrix,Marian C. Limacher,Gerardo Heiss,Charles Kooperberg,Alison E. Baird,Theodore A. Kotchen,J. David Curb,Henry R. Black,Jacques E. Rossouw,Aaron K. Aragaki,Monika M. Safford,Evan A. Stein,Somchai Laowattana,W. Jerry Mysiw +14 more
TL;DR: Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.